Company Filing History:
5 out of 204 
1 out of 832,912 Years Active: 2013-2021
Title: Innovations by Luitgard Nagel-Steger: Pioneering Peptide Research
Introduction
Luitgard Nagel-Steger, an accomplished inventor based in Langenfeld, Germany, has made significant contributions to the field of biochemistry through his innovative research. With a total of six patents to his name, Nagel-Steger focuses on peptides that have potential therapeutic applications, particularly concerning amyloid-beta conformers.
Latest Patents
Among his latest inventions is a patent titled "D-enantiomeric peptides derived from D3 and use thereof." This groundbreaking innovation relates to novel D-enantiomeric A-beta-oligomer-binding peptides, alongside their homologs, fragments, parts, and polymers, and outlines their various uses. Another significant patent is "Method for quantitative characterization of substances with regard to their properties of binding to amyloid-β (Aβ) conformers." This invention details a comprehensive method for observing and quantifying the binding properties of various substances to Aβ conformers, involving procedures such as fractionating samples and immobilizing biotinylated Aβ conformers.
Career Highlights
Luitgard Nagel-Steger has built an impressive career while working at renowned institutions, including Forschungszentrum Juelich GmbH, where he contributed to pioneering research initiatives. His work has garnered recognition in the scientific community, leading to innovative techniques and methodologies that aid in the understanding of Alzheimer’s disease mechanisms.
Collaborations
Collaboration has been pivotal in Nagel-Steger's career. He has worked closely with notable coworkers such as Dieter Willbold and Susanne Aileen Funke. Their collective expertise has propelled advancements in peptide research and the exploration of potential therapeutic targets for neurodegenerative diseases.
Conclusion
Luitgard Nagel-Steger’s contributions to the field of biochemistry stand as a testament to his innovative spirit and dedication to research. With several patents and a strong record of collaboration with esteemed colleagues, he continues to pave the way for advancements in understanding and treating diseases associated with amyloid-beta conformers. His work exemplifies the crucial intersection of innovation and scientific inquiry.